Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer

Chia Yi Su, Yu Peng Liu, Chih Jen Yang, Yuan Feng Lin, Jean Chiou, Li Hsing Chi, Jih Jong Lee, Alex T H Wu, Pei Jung Lu, Ming Shyan Huang, Michael Hsiao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background In lung cancer, uPA, its receptor (uPAR), and the inhibitors PAI-1 and PAI-2 of the plasminogen activator family interact with MMP-2 and MMP-9 of the MMP family to promote cancer progression. However, it remains undetermined which of these markers plays the most important role and may be the most useful indicator to stratify the patients by risk. Methods We determined the individual prognostic value of these 6 markers by analyzing a derivation cohort with 98 non-small cell lung cancer patients by immunohistochemical staining. The correlation between the IHC expression levels of these markers and disease prognosis was investigated, and an immunohistochemical panel for prognostic prediction was subsequently generated through prognostic model analysis. The value of the immunohistochemical panel was then verified by a validation cohort with 91 lung cancer patients. Results In derivation cohort, PAI-2 is the most powerful prognostic factor (HR = 2.30; P = 0.001), followed by MMP-9 (HR = 2.09; P = 0.019) according to multivariate analysis. When combining PAI-2 and MMP-9, the most unfavorable prognostic group (low PAI-2 and high MMP-9 IHC expression levels) showed a 6.40-fold increased risk of a poor prognosis compared to the most favorable prognostic group (high PAI-2 and low MMP-9 IHC expression levels). PAI-2 and MMP-9 IHC panel could more precisely identify high risk patients in both derivation and validation cohort. Conclusions We revealed PAI-2 as the most powerful prognostic marker among PA and MMP protease family even after considering their close relationships with each other. By utilizing a combination of PAI-2 and MMP-9, more precise prognostic information than merely using pathological stage alone can be obtained for lung cancer patients.

Original languageEnglish
Article numbere0133411
JournalPLoS One
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 31 2015

Fingerprint

Plasminogen Activator Inhibitor 2
gelatinase B
lung neoplasms
Matrix Metalloproteinases
Non-Small Cell Lung Carcinoma
Peptide Hydrolases
proteinases
Cells
cells
prognosis
Lung Neoplasms
plasminogen activator
gelatinase A
plasminogen activator inhibitors
multivariate analysis
Plasminogen Activators
Plasminogen Activator Inhibitor 1
receptors
neoplasms
prediction

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer. / Su, Chia Yi; Liu, Yu Peng; Yang, Chih Jen; Lin, Yuan Feng; Chiou, Jean; Chi, Li Hsing; Lee, Jih Jong; Wu, Alex T H; Lu, Pei Jung; Huang, Ming Shyan; Hsiao, Michael.

In: PLoS One, Vol. 10, No. 7, e0133411, 31.07.2015.

Research output: Contribution to journalArticle

Su, Chia Yi ; Liu, Yu Peng ; Yang, Chih Jen ; Lin, Yuan Feng ; Chiou, Jean ; Chi, Li Hsing ; Lee, Jih Jong ; Wu, Alex T H ; Lu, Pei Jung ; Huang, Ming Shyan ; Hsiao, Michael. / Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer. In: PLoS One. 2015 ; Vol. 10, No. 7.
@article{17a96b1db5d64c209f1baf0284c7c6df,
title = "Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer",
abstract = "Background In lung cancer, uPA, its receptor (uPAR), and the inhibitors PAI-1 and PAI-2 of the plasminogen activator family interact with MMP-2 and MMP-9 of the MMP family to promote cancer progression. However, it remains undetermined which of these markers plays the most important role and may be the most useful indicator to stratify the patients by risk. Methods We determined the individual prognostic value of these 6 markers by analyzing a derivation cohort with 98 non-small cell lung cancer patients by immunohistochemical staining. The correlation between the IHC expression levels of these markers and disease prognosis was investigated, and an immunohistochemical panel for prognostic prediction was subsequently generated through prognostic model analysis. The value of the immunohistochemical panel was then verified by a validation cohort with 91 lung cancer patients. Results In derivation cohort, PAI-2 is the most powerful prognostic factor (HR = 2.30; P = 0.001), followed by MMP-9 (HR = 2.09; P = 0.019) according to multivariate analysis. When combining PAI-2 and MMP-9, the most unfavorable prognostic group (low PAI-2 and high MMP-9 IHC expression levels) showed a 6.40-fold increased risk of a poor prognosis compared to the most favorable prognostic group (high PAI-2 and low MMP-9 IHC expression levels). PAI-2 and MMP-9 IHC panel could more precisely identify high risk patients in both derivation and validation cohort. Conclusions We revealed PAI-2 as the most powerful prognostic marker among PA and MMP protease family even after considering their close relationships with each other. By utilizing a combination of PAI-2 and MMP-9, more precise prognostic information than merely using pathological stage alone can be obtained for lung cancer patients.",
author = "Su, {Chia Yi} and Liu, {Yu Peng} and Yang, {Chih Jen} and Lin, {Yuan Feng} and Jean Chiou and Chi, {Li Hsing} and Lee, {Jih Jong} and Wu, {Alex T H} and Lu, {Pei Jung} and Huang, {Ming Shyan} and Michael Hsiao",
year = "2015",
month = "7",
day = "31",
doi = "10.1371/journal.pone.0133411",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer

AU - Su, Chia Yi

AU - Liu, Yu Peng

AU - Yang, Chih Jen

AU - Lin, Yuan Feng

AU - Chiou, Jean

AU - Chi, Li Hsing

AU - Lee, Jih Jong

AU - Wu, Alex T H

AU - Lu, Pei Jung

AU - Huang, Ming Shyan

AU - Hsiao, Michael

PY - 2015/7/31

Y1 - 2015/7/31

N2 - Background In lung cancer, uPA, its receptor (uPAR), and the inhibitors PAI-1 and PAI-2 of the plasminogen activator family interact with MMP-2 and MMP-9 of the MMP family to promote cancer progression. However, it remains undetermined which of these markers plays the most important role and may be the most useful indicator to stratify the patients by risk. Methods We determined the individual prognostic value of these 6 markers by analyzing a derivation cohort with 98 non-small cell lung cancer patients by immunohistochemical staining. The correlation between the IHC expression levels of these markers and disease prognosis was investigated, and an immunohistochemical panel for prognostic prediction was subsequently generated through prognostic model analysis. The value of the immunohistochemical panel was then verified by a validation cohort with 91 lung cancer patients. Results In derivation cohort, PAI-2 is the most powerful prognostic factor (HR = 2.30; P = 0.001), followed by MMP-9 (HR = 2.09; P = 0.019) according to multivariate analysis. When combining PAI-2 and MMP-9, the most unfavorable prognostic group (low PAI-2 and high MMP-9 IHC expression levels) showed a 6.40-fold increased risk of a poor prognosis compared to the most favorable prognostic group (high PAI-2 and low MMP-9 IHC expression levels). PAI-2 and MMP-9 IHC panel could more precisely identify high risk patients in both derivation and validation cohort. Conclusions We revealed PAI-2 as the most powerful prognostic marker among PA and MMP protease family even after considering their close relationships with each other. By utilizing a combination of PAI-2 and MMP-9, more precise prognostic information than merely using pathological stage alone can be obtained for lung cancer patients.

AB - Background In lung cancer, uPA, its receptor (uPAR), and the inhibitors PAI-1 and PAI-2 of the plasminogen activator family interact with MMP-2 and MMP-9 of the MMP family to promote cancer progression. However, it remains undetermined which of these markers plays the most important role and may be the most useful indicator to stratify the patients by risk. Methods We determined the individual prognostic value of these 6 markers by analyzing a derivation cohort with 98 non-small cell lung cancer patients by immunohistochemical staining. The correlation between the IHC expression levels of these markers and disease prognosis was investigated, and an immunohistochemical panel for prognostic prediction was subsequently generated through prognostic model analysis. The value of the immunohistochemical panel was then verified by a validation cohort with 91 lung cancer patients. Results In derivation cohort, PAI-2 is the most powerful prognostic factor (HR = 2.30; P = 0.001), followed by MMP-9 (HR = 2.09; P = 0.019) according to multivariate analysis. When combining PAI-2 and MMP-9, the most unfavorable prognostic group (low PAI-2 and high MMP-9 IHC expression levels) showed a 6.40-fold increased risk of a poor prognosis compared to the most favorable prognostic group (high PAI-2 and low MMP-9 IHC expression levels). PAI-2 and MMP-9 IHC panel could more precisely identify high risk patients in both derivation and validation cohort. Conclusions We revealed PAI-2 as the most powerful prognostic marker among PA and MMP protease family even after considering their close relationships with each other. By utilizing a combination of PAI-2 and MMP-9, more precise prognostic information than merely using pathological stage alone can be obtained for lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84941960777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941960777&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133411

DO - 10.1371/journal.pone.0133411

M3 - Article

C2 - 26230665

AN - SCOPUS:84941960777

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0133411

ER -